Logo

Galapagos Reports Results of GLPG3667 in P-Ib Study for the Treatment of Psoriasis

Share this
Galapagos Reports Results of GLPG3667 in P-Ib Study for the Treatment of Psoriasis

Galapagos Reports Results of GLPG3667 in P-Ib Study for the Treatment of Psoriasis

Shots:

  • The P-Ib study evaluates GLPG3667 (low/high dose) vs PBO in 31 patients in a ratio (1:1:1) in patients with moderate to severe plaque psoriasis for 4wks.
  • Results: 40% of patients with the high dose of GLPG3667 showed improvement of 50% in PASI response from baseline @4wks. and was well tolerated with no serious AEs. 4 patients achieved a 52%- 65%- 74% and 81% improvement in PASI score- positive efficacy signals were also observed for other endpoints-
  • The company plans to submit the results of GLPG3667 at scientific conferences for publication and in peer-reviewed medical journals. The company plans to initiate the P-IIb program of GLPG3667 for psoriasis in 2022

  Ref: Globe Newswire | Image: Nature

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions